17α-Hydroxyprogesterone

Biological activity

17α-OHP is an agonist of the progesterone receptor (PR) similarly to progesterone, albeit weakly in comparison. In addition, it is an antagonist of the mineralocorticoid receptor (MR) as well as a partial agonist of the glucocorticoid receptor (GR), albeit with very low potency (EC50 100-fold less relative to cortisol) at the latter site, also similarly to progesterone.

Biochemistry

Biosynthesis

17α-OHP is derived from progesterone via 17α-hydroxylase (encoded by CYP17A1).

17α-OHP increases in the third trimester of pregnancy primarily due to fetal adrenal production.

This steroid is primarily produced in the adrenal glands and to some degree in the gonads, specifically the corpus luteum of the ovary. Normal levels are 3-90 ng/dl in children, and in women, 20-100 ng/dl prior to ovulation, and 100-500 ng/dl during the luteal phase.

Measurement

Measurements of levels of 17α-OHP are useful in the evaluation of patients with suspected congenital adrenal hyperplasia as the typical enzymes that are defective, namely 21-hydroxylase and 11β-hydroxylase, lead to a build-up of 17α-OHP. In contrast, the rare patient with 17α-hydroxylase deficiency will have very low or undetectable levels of 17α-OHP. 17α-OHP levels can also be used to measure contribution of progestational activity of the corpus luteum during pregnancy as progesterone but note, 17α-OHP is also contributed by the placenta.

Immunoassays like RIA (radioimmunoassay) or IRMA (immunoradiometric assay) used to clinically determine 17α-OHP are prone to cross-reactivity with the 17α-OHP steroid precursors and their sulphated conjugates. Gas or liquid chromatography and mass spectrometry (e.g. LC-MS/MS) achieves greater specificity than immunoassays.

Measurement of 17α-OHP by LC-MS/MS improves newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, because 17α-OHP steroid precursors and their sulphated conjugates which are present in the first two days after birth and longer in pre-term neonates, cross-react in immunoassays with 17α-OHP, giving falsely high 17α-OHP levels.

Pharmacology

Pharmacokinetics

Although 17α-OHP has not been used as a medication, its pharmacokinetics have been studied and reviewed.

Medical uses

Esters of 17α-OHP, such as hydroxyprogesterone caproate and, to a far lesser extent, hydroxyprogesterone acetate and hydroxyprogesterone heptanoate, have been used in medicine as progestins.

Chemistry

17α-OHP is the parent compound of a class of progestins referred to as the 17α-hydroxyprogesterone derivatives. Among others, this class of drugs includes chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate.

Society and culture

Generic names

Hydroxyprogesterone is the generic name of 17α-OHP and its and .

References

References

1. "17-hydroxyprogesterone (17OHP)".
2. J. Elks. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
3. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
4. (January 2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis.
5. (2007). "Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins". Am. J. Obstet. Gynecol..
6. (April 2015). "Influence of 17-Hydroxyprogesterone, Progesterone and Sex Steroids on Mineralocorticoid Receptor Transactivation in Congenital Adrenal Hyperplasia". Horm Res Paediatr.
7. (2015). "Adrenal Steroid Metabolites Accumulating in Congenital Adrenal Hyperplasia lead to Transactivation of the Glucocorticoid Receptor". Endocrinology.
8. (2012). "Progesterone Acts via the Nuclear Glucocorticoid Receptor to Suppress IL-1β-Induced COX-2 Expression in Human Term Myometrial Cells". PLOS ONE.
9. (2015). "A case of 17 alpha-hydroxylase deficiency". The Korean Society for Reproductive Medicine.
10. (2021-03-18). "Endocrinology of Pregnancy". MDText.com, Inc..
11. [http://www.perinatology.com/Reference/Reference%20Ranges/17-hydroxyprogesterone.htm Reference Values During Pregnancy]
12. "normal ranges for hormone tests in women".
13. (2020-08-23). "Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy". MDPI AG.
14. (1990). "17-Hydroxyprogesterone level as a marker for corpus luteum function in aborters versus nonaborters". International Journal of Fertility.
15. (March 2020). "Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand". International Journal of Neonatal Screening.
16. (September 2019). "Wisconsin's Screening Algorithm for the Identification of Newborns with Congenital Adrenal Hyperplasia". International Journal of Neonatal Screening.
17. (27 November 2013). "Die Gestagene". Springer-Verlag.
18. Jeffrey K. Aronson. (21 February 2009). "Meyler's Side Effects of Endocrine and Metabolic Drugs". Elsevier.
19. (31 July 2000). "Forensic Management of Sexual Offenders". Springer Science & Business Media.
20. (1 January 1983). "Introduction to the Principles of Drug Design". Elsevier.